The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Development of biomarkers in multiple sclerosis
Abstract
Multiple sclerosis is a complex disease, as several pathophysiological processes (including inflammation, demyelination, axonal damage and repair mechanisms) participate in the disease process. Furthermore, as new pathological evidence reveals, these processes are not uniformly represented across patient populations but can selectively predominate in individual patients, thus contributing to the heterogeneity in phenotypic expression of the disease, its prognosis and response to therapies. While the armamentarium of available therapies for multiple sclerosis broadens, little is known about factors that predict treatment response in individual patients to a specific drug. More importantly, we are beginning to understand that, analogous to cancer therapy, the successful therapeutic strategy in multiple sclerosis might ultimately involve the combination of different therapeutics targeting several dominant pathophysiological processes. The development of these process-specific therapies will be impossible without the use of biomarkers that reflect the targeted process, can select patient population in which the targeted process is prevailing and can aid during the more rapid screening of therapeutic agents in the early phase of their development. This review summarizes the general concepts of biomarkers and their potential use as surrogate endpoints and tailors these concepts to specific applications in multiple sclerosis research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Users' guides to the medical literature
Guyatt, G. H. (1993) · JAMA · doi:10.1001/jama.270.17.2096 · Cited by 2,970
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Strober, S., Cannella, B., Allard, J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-500 · Cited by 1,669
Jaeschke, R. (1994) · JAMA · doi:10.1001/jama.1994.03510290071040 · Cited by 1,049
Identification of autoantibodies associated with myelin damage in multiple sclerosis
Genain, C. P., Cannella, B., Hauser, S. L., & Raine, C. S. (1999) · Nature Medicine · doi:10.1038/5532 · Cited by 892
Bielekova, B., Goodwin, B., Richert, N., Cortese, I., Kondo, T., Afshar, G., Gran, B., Eaton, J., Antel, J., Frank, J. A., et al. (2000) · Nature Medicine · doi:10.1038/80516 · Cited by 823
Self-citationClinical biomarkers in drug discovery and development
Frank, R., & Hargreaves, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1130 · Cited by 794
Glutamate excitotoxicity in a model of multiple sclerosis
Pitt, D., Werner, P., & Raine, C. S. (2000) · Nature Medicine · doi:10.1038/71555 · Cited by 744
The validation of surrogate endpoints in meta-analyses of randomized experiments
Buyse, M., Molenberghs, G., Burzykowski, T., Renard, D., & Geys, H. (2000) · Biostatistics · doi:10.1093/biostatistics/1.1.49 · Cited by 624
Durelli, L., Verdun, E., Barbero, P., Bergui, M., Versino, E., Ghezzi, A., Montanari, E., & Zaffaroni, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08430-1 · Cited by 547
John, G. R., Shankar, S. L., Shafit-Zagardo, B., Massimi, A., Lee, S. C., Raine, C. S., & Brosnan, C. F. (2002) · Nature Medicine · doi:10.1038/nm781 · Cited by 477
Lesko, L., & Atkinson, A. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.347 · Cited by 465
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results
Li, D. K. B., Zhao, G. J., Paty, D. W., & the University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1505 · Cited by 458
Remyelination in multiple sclerosis
Piaton, G., Williams, A., Seilhean, D., & Lubetzki, C. (2009) · Progress in Brain Research · doi:10.1016/s0079-6123(09)17530-1 · Cited by 441
Hayward, R. S. A. (1995) · JAMA · doi:10.1001/jama.1995.03530070068032 · Cited by 381
Paolillo, A., Coles, A. J., Molyneux, P. D., Gawne–Cain, M., MacManus, D., Barker, G. J., Compston, D. A. S., & Miller, D. H. (1999) · Neurology · doi:10.1212/wnl.53.4.751 · Cited by 220
Bomprezzi, R., Ringnér, M., Kim, S., Bittner, M. L., Khan, J., Chen, Y., Elkahloun, A., Yu, A., Bielekova, B., Meltzer, P. S., et al. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg221 · Cited by 213
Self-citationRecent clinical trials of hydroxyzine in generalized anxiety disorder
Ferreri, M., & Hantouche, E. G. (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb05974.x · Cited by 211
Wandinger, K.-P., Lünemann, J. D., Wengert, O., Bellmann-Strobl, J., Aktas, O., Weber, A., Grundström, E., Ehrlich, S., Wernecke, K.-D., Volk, H.-D., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13641-0 · Cited by 207
Cutting Edge: Molecular Portrait of Human Autoimmune Disease
Maas, K., Chan, S., Parker, J., Slater, A., Moore, J., Olsen, N., & Aune, T. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.5 · Cited by 202
Remyelination in multiple sclerosis
Brück, W., Kuhlmann, T., & Stadelmann, C. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00191-0 · Cited by 200
Remyelination in multiple sclerosis
Lassmann, H., Brück, W., Lucchinetti, C., & Rodriguez, M. (1997) · Multiple Sclerosis Journal · doi:10.1177/135245859700300213 · Cited by 191
Wandinger, K., Stürzebecher, C., Bielekova, B., Detore, G., Rosenwald, A., Staudt, L. M., McFarland, H. F., & Martin, R. (2001) · Annals of Neurology · doi:10.1002/ana.1096 · Cited by 177
Self-citationLinomide in relapsing and secondary progressive MS: Part I: Trial design and clinical results
Noseworthy, J. H., Wolinsky, J. S., Lublin, F. D., Whitaker, J. N., Linde, A., Gjorstrup, P., Sullivan, H. C., & the North American Linomide Investigators (2000) · Neurology · doi:10.1212/wnl.54.9.1726 · Cited by 174
Stürzebecher, S., Wandinger, K. P., Rosenwald, A., Sathyamoorthy, M., Tzou, A., Mattar, P., Frank, J. A., Staudt, L., Martin, R., & McFarland, H. F. (2003) · Brain · doi:10.1093/brain/awg147 · Cited by 168
Self-citationWhitney, L. W., Ludwin, S. K., McFarland, H. F., & Biddison, W. E. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00438-6 · Cited by 152
Mycko, M. P., Papoian, R., Boschert, U., Raine, C. S., & Selmaj, K. W. (2003) · Brain · doi:10.1093/brain/awg107 · Cited by 152
Linomide in relapsing and secondary progressive MS: Part II: MRI results
Wolinsky, J. S., Narayana, P. A., Noseworthy, J. H., LUBLIN, F. D., Whitaker, J. N., Linde, A., Gjörstrup, P., & Sullivan, H. C. (2000) · Neurology · doi:10.1212/wnl.54.9.1734 · Cited by 143
Statistical challenges in the evaluation of surrogate endpoints in randomized trials
Molenberghs, G., Buyse, M. E., Geys, H., Renard, D., Burzykowski, T., & Alonso, A. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00236-2 · Cited by 131
Perspective: Validating Surrogate Markers--Are We Being Naive?
Gruttola, V. D., Fleming, T. R., Lin, D. Y., & Coombs, R. W. (1997) · The Journal of Infectious Diseases · doi:10.1093/infdis/175.2.237 · Cited by 130
Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance
Barkhof, F., & van Walderveen, M. A. A. (1999) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.1999.0511 · Cited by 125
The role of MRI as a surrogate outcome measure in multiple sclerosis
McFarland, H. F., Barkhof, F., Antel, J. P., & Miller, D. (2002) · Multiple Sclerosis Journal · doi:10.1177/135245850200800109 · Cited by 122
Mechanisms of demyelination and tissue destruction in multiple sclerosis
Lassmann, H. (2002) · Clinical Neurology and Neurosurgery · doi:10.1016/s0303-8467(02)00033-1 · Cited by 105
Rieckmann, P., Altenhofen, B., Riegel, A., Baudewig, J., & Felgenhauer, K. (1997) · Annals of Neurology · doi:10.1002/ana.410410307 · Cited by 102
Longitudinal study of soluble adhesion molecules in multiple sclerosis
Giovannoni, G., Lai, M., Thorpe, J. E., et al. (1997) · Neurology · doi:10.1212/wnl.48.6.1557 · Cited by 92
A new paraclinical CSF marker for hypoxia‐like tissue damage in multiple sclerosis lesions
Lassmann, H., Reindl, M., Rauschka, H., Berger, J., Aboul‐Enein, F., Berger, T., Zurbriggen, A., Lutterotti, A., Brück, W., Weber, J. R., et al. (2003) · Brain · doi:10.1093/brain/awg127 · Cited by 53
Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis
Kraus, J., Oschmann, P., Engelhardt, B., Schiel, C., Hornig, C. R., Bauer, R., Kern, A., Traupe, H., & Dorndorf, W. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1998.tb01727.x · Cited by 43
Hughes, M. D., DeGruttola, V., & Welles, S. L. (1995) · PubMed · Cited by 29
Kagan, J. (1998) · Disease Markers · doi:10.1155/1998/698239 · Cited by 16
Urinary markers of disease activity in multiple sclerosis
Giovannoni, G., & Thompson, E. J. (1998) · Multiple Sclerosis Journal · doi:10.1177/135245859800400330 · Cited by 14
Are there any body fluid markers of brain atrophy in multiple sclerosis?
Giovannoni, G., Green, A. J. E., & Thompson, E. J. (1998) · Multiple Sclerosis Journal · doi:10.1177/135245859800400310 · Cited by 9
Diagnostic criteria for primary progressive mutiple sclerosis: a position paper.
(2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200006)47:6 · Cited by 2
Cited by
Immunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
Self-citationA consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
Teunissen, C. E., Petzold, A., Bennett, J. L., Berven, F. S., Brundin, L., Comabella, M., Franciotta, D., Frederiksen, J. L., Fleming, J. O., Furlan, R., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c47cc2 · Cited by 845
Miller, D., Barkhof, F., Montalban, X., Thompson, A., & Filippi, M. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70071-5 · Cited by 594
Keller, A., Leidinger, P., Lange, J., Borries, A., Schroers, H., Scheffler, M., Lenhof, H.-P., Ruprecht, K., & Meese, E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007440 · Cited by 370
Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging
Haacke, E. M., Makki, M., Ge, Y., Maheshwari, M., Sehgal, V., Hu, J., Selvan, M., Wu, Z., Latif, Z., Xuan, Y., et al. (2009) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21676 · Cited by 329
Metadata
- Authors
- Bielekova, B., & Martin, R.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-07
- Volume
- 127
- Issue
- 7
- Pages
- 1463-1478
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2119412335
- Cited by
- 299
- References
- 46
- FWCI
- 13.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.